AI

#AI #Drug Discovery 2022 #Genomics #Immunology #Nanomedicine / nanotechnology #Personalised medicine

Sharing knowledge to fuel the revolution

Here, we speak with two of the keynote speakers at this year’s Drug Discovery 2022, Molly Stevens, Professor of Biomedical Materials and Regenerative Medicine at Imperial College London, and Rab Prinjha, VP Head of Immunology Research Unit at GlaxoSmithKline, about the insights they will be sharing and what they see as the… Read More

#Exclusive Content

#AI #AI / data analytics / healthtech / informatics #Automation / robotics #Drug discovery #Drug Discovery 2022 #ELRIG

DDW Fall 2022 issue out with Drug Discovery 2022 supplement

The Fall Issue of the Drug Discovery World Magazine is out now.   Featuring Specialty Spotlight on Neuroscience, the magazine is available to download and read for free on the DDW App.   Key features of the Fall Issue include How AI in Pharma Can Live Up… Read More

#News

#AI #Biotechnology #Collaboration #Drug discovery #Pfizer

Pfizer and CytoReason collaborate to bolster AI in drug discovery

Pfizer has extended its multi-year partnership with CytoReason to use CytoReason’s artificial intelligence (AI) technology for Pfizer’s drug development programs.   Pfizer will make a $20 million equity investment, have options to license CytoReason’s platform and disease models, and fund supplementary project support. This deal which has the potential to be worth up… Read More

#Business & Investment #News

Automation
#AI #Automation / robotics #Drug discovery #Sustainability

How can automation help in the discovery of biologics?

Zoe Hughes-Thomas, GSK, will be discussing the ways in which Automation Can Help With The Discovery of Biologics and Biosimilars at the new Tech Theatre at this year’s ELRIG Drug Discovery, supported by DDW. Hughes-Thomas is Associate Director, Head Medicine Design Automation, GSK. The Tech… Read More

#Editor's Choice #News

#AI #Artificial intelligence (AI) #Drug discovery #R&D

Industry partnership to boost AI in drug discovery

A new partnership will bring together Microsoft’s computational services, cloud and artificial intelligence (AI) and Novo Nordisk’s drug discovery, development and data science capabilities. Through the agreement, Microsoft will provide AI technology, foundational science models and expertise and work alongside Novo Nordisk’s data scientists and domain experts to accelerate the… Read More

#Business & Investment #News

Virtual reality in medical research
#AI #Artificial intelligence (AI) #Automation / robotics #Drug Discovery 2022 #Lab automation

Lab of the future uncovered at Drug Discovery 2022

Nicola Richmond, VP of AI, BenevolentAI, will be speaking at the Tech Theatre, ELRIG Drug Discovery 2022, supported by DDW. Nicola Richmond is a mathematician with over 20 years’ experience of developing digital solutions to problems in drug discovery and development. She will be presenting a talk on ‘The lab… Read More

#Editor's Choice #News

Chest CT images
#AI #Artificial intelligence (AI) #Idiopathic pulmonary fibrosis #Imaging #Lung disease

Phase II IPF trial to benefit from AI imaging

Brainomix has partnered with Bridge Biotherapeutics to deliver AI imaging biomarker analysis within the Phase II study of novel autotaxin inhibitor BBT-877 in idiopathic pulmonary fibrosis (IPF). Under the partnership, Brainomix will leverage its e-ILD technology (automated artificial intelligence software) which has been trained to process high resolution chest CT… Read More

#News

#AI #Machine learning #Software

AI in R&D: From hot topic to practical application 

This paid-for advertorial by Benchling appeared in the DDW ebook – AI in drug discovery: How technology is driving innovation. By Ashoka Rajendra, Head of Development & Manufacturing Products at Benchling Artificial Intelligence (AI) is emblematic of the new era of modern biotech — data-driven, collaborative and ultimately, faster than… Read More

#Business & Investment #Exclusive Content #Opinion #Trends & Analysis

#AI #AI / data analytics / healthtech / informatics #Machine learning #Pharma

Intelligent designs: How pharma researchers are using AI 

DDW Editor Reece Armstrong explores how AI is being utilised in the lab and what the technology can really do within pharma.  Artificial intelligence (AI), a branch of computer science encompassing machine learning and deep learning, and which technologies such as automation, natural language processing (NLP) and image recognition all… Read More

#Business & Investment #Exclusive Content #Opinion #Trends & Analysis

#AI #Biotechnology #Pharma

Making its mark: AI in drug discovery 

The concept of Artificial Intelligence (AI) never fails to stimulate and in drug discovery the possibilities it presents, the potential it holds, are always thought-provoking, says DDW Publishing Director Lu Rahman.  The simulation of human intelligence processes by machines finds itself at an exciting moment for use within the drug… Read More

#Exclusive Content #Opinion #Trends & Analysis

#AI #Drug discovery #Machine learning #Oncology

The role of machine learning in cancer drug development

Throughout the continuum of drug development, from target discovery to patient selection, machine learning approaches are being adopted to reliably mine vast amounts of data and make predictions with higher accuracy Anita Ramanathan discusses how machine learning is currently used across different stages of cancer research.  Applying computational methods to… Read More

#Cancer Research #Exclusive Content

AI
#AI #Funding #Pharmaceutical

AI platform for pharma raises €12.1 million  

Technology company PeakData has raised €12.1 million in Series A funding to support its artificial intelligence (AI) platform.  Launched in 2018, PeakData enables pharmaceutical companies to uncover the whole therapeutic area by mapping the healthcare professionals (HCPs) most relevant to their target market. It’s hoped that this… Read More

#News

#AI #Chronic pain #Finance #Funding #Start-ups #Stem cells

International start-ups receive funding from BioInnovation 

Three international life sciences start-ups have received investment from the BioInnovation Institute (BII).   The three new ventures were chosen as part of the BII’s focus on developing scientific initiatives across the therapeutics and health tech space.  The companies, Sevenless Therapeutics, VEIL.AI and Myopax, will receive €1.3 million and will form… Read More

#Business & Investment #News

#AI #Business #Investment

Sanofi signs $20m research agreement with Atomwise  

Artificial intelligence (AI) company Atomwise has signed an exclusive research collaboration with Sanofi to use its AtomNet platform for computational discovery and research of up to five drug targets.  The agreement will see Atomwise receive $20 million from Sanofi to identify, synthesise, and advance lead compounds for up to five targets,… Read More

#Business & Investment #News

#AI #AI / data analytics / healthtech / informatics #Automation / robotics

How end-to-end laboratory automation and AI are accelerating drug discovery

The next era of laboratory automation is no longer about sample movers or liquid handlers. With big data being the central focus, several new trends have emerged in this space, making laboratory automation better, more powerful, and more accessible. By Anita Ramanathan. Automation goals once revolved around ‘getting more done’. Read More

#Exclusive Content

DNA
#AI #Multi-omics #Precision medicine

Partnership to advance precision medicine for metabolic disease  

Drug discovery company MultiOmic Health and digital health start-up Mesh Bio will work together on an observational clinical study for patients with chronic metabolic disease and increased risk of complications such as chronic kidney disease.   The partnership will provide access to data from patient populations in Asia… Read More

#News